Alaunos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2024 Ended Sep 30, 2024 | Oct 10, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | $0 | $-0.04 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | $4.00K | $-0.04 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 10, 2023 | Before market open | – | $-0.04 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 7, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 16, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 30, 2022 | Before market open | – | – | – |
| Q1 FY2021 Ended Jun 30, 2021 | Aug 9, 2021 | After market close | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Feb 25, 2021 | After market close | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 5, 2020 | After market close | – | – | – |
Press releases
Announcements Alaunos Therapeutics filed with the SEC
Transaction & Corporate Overview October 2026 Confidential
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Material agreement · Other events · EX-99.1 to Form 8-K
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued
Results of operations · Listing notice · EX-99.1 to Form 8-K
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim
Results of operations · EX-99.1 to Form 8-K
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Alaunos Therapeutics to Present Data Highlighting its
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
Other events · EX-99.1 to Form 8-K
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy
Regulation FD disclosure · EX-99.1 to Form 8-K
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase
Other events · EX-99.1 to Form 8-K
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Oppenheimer 32nd Annual Healthcare Conference March 2022
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K